Theravance Biopharma Q4 2023 GAAP EPS $(0.17) Misses $(0.15) Estimate, Sales $17.57M Miss $17.68M Estimate
Theravance Biopharma Q4 2023 GAAP EPS $(0.17) Misses $(0.15) Estimate, Sales $17.57M Miss $17.68M Estimate
Theravance Biopharma 2023年第四季度GAAP每股收益（0.17）未達到預期（0.15）美元，銷售額爲1757萬美元，未達到1768萬美元的預期
Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. The company reported quarterly sales of $17.57 million which missed the analyst consensus estimate of $17.68 million by 0.67 percent. This is a 19.91 percent increase over sales of $14.65 million the same period last year.
Theravance Biopharma（納斯達克股票代碼：TBPH）公佈的季度虧損爲每股0.17美元，比分析師普遍預期的0.15美元（0.15美元）低13.33％。該公司公佈的季度銷售額爲1757萬美元，比分析師普遍預期的1768萬美元低0.67％。這比去年同期的1465萬美元銷售額增長了19.91％。